Why ‘world’s most powerful weight-loss drug’ is so effective as surprising side effects of injections revealed
The weight loss drug market is rapidly expanding and a new release being cited as the 'world's most powerful' could soon be commonplace.
Over the past few years, the likes of Ozempic, Mounjaro and Wegovy have all become incredibly popular, despite the various side effects that have been associated with them, and it's easy to understand why.
In a society which is unhealthily obsessed with the way people look, a drug which is marketed as a quick and easy way to lose weight without the need to diet or exercise was always likely to do well.
But now Retatrutide could potentially blow the other drugs out of the water when it comes to effectiveness, with developers Eli Lilly describing the new GLP-1 option as the best out there, and there's a specific reason why it is so effective.
Advert
Unlike others on the market, Retatrutide is a 'triple agonist', which essentially means that it activates three distinct metabolic pathways simultaneously, as opposed to the other well-known brands which target one or two at most.
Retatrutide, which is expected to officially arrive in the UK in 2027 or 2028, has shown off some impressive results in testing and this is likely because it targets GLP-1, GIP and Glucagon all at once. Although it seems as if the usual gastrointestinal problems will persist.
Now you might be wondering what the heck that means and why it could be so powerful. It is mainly because of this added third ingredient of Glucagon, which differs from the receptors GLP-1 and GIP, as they primarily control the 'input' side of energy balance by reducing food intake and managing blood sugar.
Glucagon meanwhile takes a more active approach to weight loss, as it actively increases the amount of energy you expend, and therefore burns more calories and promotes the breakdown of stored fat and liver fat.
The concept of a drug which actively burns calories for you is perhaps always going to be appealing and it seems as if many aren't willing to wait until it officially hits shelves in the US and the UK, as there have been numerous cases of people getting their hands on an experimental version of the drug.
ASDA Online Doctor's Dr Kathryn Basford previously warned against consuming the medication, saying that drugs which have not received official approval are 'likely illegal and potentially dangerous'.
"Because Retatrutide isn’t licensed for use in the UK yet, suppliers claiming to sell it for personal use are likely illegal and potentially dangerous," Dr Basford explained, adding that the drug is unlikely to get approval until 2027 or 2028.
"Taking any form of medication before official approval is never advised and should be avoided at all costs."
But when it does become more widely available, there's little doubt that it will prove popular, especially after a performance in trials where it was compared with Mounjaro, which is also developed by Eli Lilly.
Those people taking Mounjaro shed an average of 26.6 percent of their body weight over 84 weeks compared to an 80 week period with Retatrutide where the average weight loss climbed to 28.3 percent.
Although there will be several side effects associated with the medication, and it's always worth speaking to a medical professional before deciding to take it, these results suggest that weight loss drug users will suddenly rediscover their appetite when Retatrutide becomes a safe and legal option for them.
Topics: Ozempic
James Moorhouse